Agile Therapeutics Chief Medical Officer, Marie Foegh, MD, Named One of New Jersey's Best 50 Women in Business by NJBiz

PRINCETON, NJ--(Marketwire - Feb 6, 2013) - Agile Therapeutics announced today that Dr. Marie Foegh, the company's Chief Medical Officer and Vice President of Clinical Research and Development, has been named one of New Jersey's Best 50 Women in Business by NJBiz.

The Best 50 Women in Business awards program honors New Jersey's most dynamic women in business that have been making headlines in their field. An independent panel of judges selected the top 50 winners based on their dedication to business growth, professional and personal accomplishments, community involvement, and advocacy for women.

"We are truly fortunate to have the opportunity to recognize this outstanding group of women," said Thomas Curtin, publisher of NJBIZ. "As business and community leaders, they are constantly redefining success within and outside the business arena. On behalf of NJBIZ, we would like to thank and congratulate these fifty outstanding women for their dedication to New Jersey's future."

Agile is developing a once-weekly contraceptive patch, AG200-15, designed to deliver a low daily dose of hormones, as well as a pipeline of other women's health products. 

"We are extremely proud of Marie for receiving this well-deserved recognition," said Al Altomari, President and CEO of Agile. "She has played an instrumental role in the development of Agile's pipeline of contraceptive products and its successful efforts to file the NDA for AG200-15, and also serves as a role model of leadership to her students and colleagues."

NJBIZ and the program sponsors will honor this year's winners during an awards ceremony on Thursday, March 21, 2013 at The Palace at Somerset Park in Somerset, NJ. The honorees will also be highlighted in a special supplement to NJBIZ on March 25, 2013.

About AG200-15
AG200-15 is an investigational combination hormonal contraceptive patch, designed to deliver a low dose of ethinyl estradiol comparable to low-dose combination oral contraceptives. The phase III trials for AG200-15 enrolled nearly 2,000 women and formed the basis for the Company's application to the US Food and Drug Administration in 2012.

The AG200-15 patch is intended to be applied once weekly for three weeks, followed by a fourth, patch-free week. The patch is designed using a soft, flexible cloth, with a silky feel, and is intended to provide excellent adhesion, comfort, and appearance.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and potentially more convenient methods of hormonal contraception. The Company's lead investigational product, AG200-15, is designed to be a once-weekly contraceptive patch that has recently been submitted to the FDA as a New Drug Application (NDA) for review. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that has been designed to allow stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.